ARTICLE | Company News
FibroGen, AstraZeneca deal
July 18, 2016 7:00 AM UTC
FibroGen said it received a scheduled $62 million license payment from AstraZeneca under a 2013 deal to develop and commercialize FibroGen’s roxadustat. The small molecule inhibitor of hypoxia-induci...